Taiwan News

AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function

AB Science SA (Euronext - FR0010557264 - AB) today announced the publication of a new article on the preprint platform MedRxiv, presenting a post-hoc subgroup analysis of the phase 2b/3 AB10015 study ...
Business Insider

AB Science announces the postponement of its annual general shareholders’ meeting

AB Science SA (Euronext - FR0010557264 - AB) today announces the postponement of its annual general shareholders’ meeting. In the exceptional context of the Covid-19 pandemic and in accordance with ...
Morningstar

AB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch

AB Science SA (Euronext - FR0010557264 - AB) today announces that The Life Sciences Magazine, a leading publication in the fields of healthcare and medical advancements, has featured an exclusive ...
Morningstar

AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection

While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are ...
Business Insider

AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939

AB SCIENCE RELEASES INITIAL DATA ON THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA (AML): THE FIRST THREE PATIENTS, ALL OF WHOM HAVE AML ...
Yahoo UK & Ireland

AB Science announces that the masitinib phase 3 study in Alzheimer's disease has completed patient recruitment

AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specialized in the research, development and marketing of protein kinase inhibitors (PKIs), announces today that the ...
Yahoo Finance

AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share

AB SCIENCE ANNOUNCES THE INITIATION OF COVERAGE OF ITS STOCK BY MAXIM GROUP WITH A TARGET PRICE OF EUR 4.0 PER SHARE AB Science SA (Euronext - FR0010557264 - AB) announces the initiation of coverage ...
WOOD-TV

AB Science reports a first complete bone marrow response in a relapsed refractory acute myeloid leukemia patient from the very low dose arm of its AB8939 Phase I/II clinical ...

AB Science SA (Euronext – FR0010557264 – AB) today announces a case report from the initial stage of its Phase I/II study (AB18001) evaluating AB8939, a microtubule destabilizer, in patients with ...
WGHP

AB Science - Summary of the presentation on masitinib in ALS delivered at 2023 AAN Annual Meeting

AB Science SA (Euronext – FR0010557264 – AB) today summarizes the presentation that was made on masitinib in amyotrophic lateral sclerosis (ALS) at the American Academy of Neurology (AAN) 2023 Annual ...
Yahoo Finance

AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers

AB Science SA (Euronext - FR0010557264 - AB) today announced the publication of a new article on the preprint platform bioRxiv. This article is entitled ‘Identification of AB8939, a novel synthetic ...
manilatimes

AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function

Albert Ludolph, MD, lead author and Senior Professor of Neurology at the University of Ulm, stated: "Our findings highlight the importance of early intervention in ALS with masitinib, demonstrating ...